Appili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
HALIFAX, Nova Scotia, April 26, 2024 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000 (the “Bridge Loan”) from Bloom Burton & Co. Inc. (the “Lender”). The Bridge Loan evidenced by a grid promissory note in favor of the Lender pursuant to which further advances may be made from time to time as agreed to by the Company and the Lender, subject to any requisite regulatory and third party consents.
Related news for (APLIF)
- Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.
- Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.
- Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia
- Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®™
- Appili Therapeutics Seeks $117.5M in Funding and Provides Aditxt Deal Updates